Praxis Precision Medicines (NASDAQ:PRAX) Sets New 52-Week High – Still a Buy?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares reached a new 52-week high on Wednesday . The company traded as high as $382.97 and last traded at $382.97, with a volume of 359778 shares trading hands. The stock had previously closed at $370.68.

Key Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $1,201 price target, implying substantial potential upside from current levels. The firm also improved its FY2026 EPS forecast to a loss of $14.09 from a prior loss estimate of $14.49, raised its FY2027 forecast to a loss of $4.24 from $5.33, and increased its projected profitability for FY2028 through FY2030. Its long-term FY2030 EPS estimate rose to $139.61 from $125.74. These revisions reinforce the investment case that Praxis could transition from development-stage losses to significant earnings if its programs succeed. HC Wainwright estimates
• Positive Sentiment: RBC Capital reaffirmed its Buy rating on Praxis, providing additional sell-side support and helping sustain bullish sentiment around the company’s neurological medicine pipeline. RBC Capital Buy rating
• Positive Sentiment: Praxis was identified as one of four biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical readouts. Such events can materially affect valuation, particularly for a high-beta biotechnology stock. Zacks biotech catalysts article
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day short-interest ratio. Because the figures show no measurable short position, the update offers little evidence of either short-covering support or bearish pressure.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $4.15 from $3.86 and continues to project losses through FY2027. This highlights near-term cash-burn and execution risks, despite much stronger projected earnings beginning in FY2028.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PRAX shares. Wedbush cut their target price on shares of Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a research note on Tuesday, June 2nd. The Goldman Sachs Group began coverage on Praxis Precision Medicines in a report on Monday, July 13th. They set a “buy” rating and a $447.00 target price on the stock. Robert W. Baird set a $514.00 price target on Praxis Precision Medicines in a report on Friday, August 7th. Wells Fargo & Company reiterated a “positive” rating and set a $362.00 price objective (up from $323.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $462.00 target price (up from $449.00) on shares of Praxis Precision Medicines in a report on Friday, August 7th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Praxis Precision Medicines currently has a consensus rating of “Buy” and a consensus target price of $573.05.

Praxis Precision Medicines Trading Up 4.2%

The firm’s 50-day simple moving average is $306.88 and its 200 day simple moving average is $316.49. The stock has a market cap of $10.79 billion, a P/E ratio of -29.88 and a beta of 2.78.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.67) by $0.80. On average, analysts anticipate that Praxis Precision Medicines, Inc. will post -14.16 EPS for the current year.

Insider Activity at Praxis Precision Medicines

In other news, Director Jill Desimone sold 11,600 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the completion of the sale, the director directly owned 2,337 shares of the company’s stock, valued at $727,554.84. This trade represents a 83.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Praxis Precision Medicines

Institutional investors and hedge funds have recently bought and sold shares of the stock. Orbis Allan Gray Ltd purchased a new position in Praxis Precision Medicines during the fourth quarter valued at approximately $369,946,000. Janus Henderson Group PLC lifted its position in shares of Praxis Precision Medicines by 17.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock worth $954,834,000 after buying an additional 476,227 shares during the last quarter. Barclays PLC boosted its stake in shares of Praxis Precision Medicines by 592.6% during the 4th quarter. Barclays PLC now owns 530,751 shares of the company’s stock worth $156,434,000 after acquiring an additional 454,114 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Praxis Precision Medicines by 63.4% during the 4th quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock valued at $332,021,000 after acquiring an additional 437,000 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in Praxis Precision Medicines by 27.6% during the fourth quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock worth $588,297,000 after purchasing an additional 431,432 shares during the period. Institutional investors and hedge funds own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.